<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03952793</url>
  </required_header>
  <id_info>
    <org_study_id>2018/63</org_study_id>
    <nct_id>NCT03952793</nct_id>
  </id_info>
  <brief_title>Organoids From Metastases of Prostate Cancer</brief_title>
  <acronym>OrMePro</acronym>
  <official_title>Development of the Organoids Technique From Metastases From Patients With Advanced Form of Prostate Cancer: Use in Basic Research</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Antoine Lacassagne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre Méditerranéen de Médecine Moléculaire UMR_S-1065</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Antoine Lacassagne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is the development of the organoid culture technique from metastases&#xD;
      from patients with advanced form of prostate cancer. Once the technique is set up, the&#xD;
      organoid will serve to test several antitumor molecules.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Feasibility issues&#xD;
  </why_stopped>
  <start_date type="Actual">December 4, 2019</start_date>
  <completion_date type="Actual">October 25, 2021</completion_date>
  <primary_completion_date type="Actual">October 25, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Success rate of establishment of the organoid culture</measure>
    <time_frame>15 days</time_frame>
    <description>The success rate is defined by the rate of successful cell culture. A Cell culture is successful when organoids grow from dividing cells</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Drugs testing on organoid for cell viability</measure>
    <time_frame>20 days</time_frame>
    <description>Viable cell count in different cells culture conditions using Cell titer Glo and viable cell count using typan blue</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cell Apoptosis Molecular and cellular mechanisms of drugs responses</measure>
    <time_frame>20 days</time_frame>
    <description>Apoptosis biomarkers analysis in microscopy. Caspase 3 will be assess using microspcopy .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cell proliferation Molecular and cellular on mechanisms of drugs responses</measure>
    <time_frame>20 days</time_frame>
    <description>Proliferative biomarkers analysis in microscopy. Ki67 will be assess using microspcopy .</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Prostatic Neoplasm</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Extended biopsy</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>extended biopsy</intervention_name>
    <description>Additional sample are performed during a biopsy to provide tumor tissues for the organoid technique development</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient with metastatic prostate cancer&#xD;
&#xD;
          -  Patient having a biopsy programmed as part of his care.&#xD;
&#xD;
          -  Patient having a biopsy programmed as part of hiscare.&#xD;
&#xD;
          -  Patient with sufficient tumor volume after imaging data review by the radiologist to&#xD;
             guarantee a sufficient quantity of material for the diagnosis of biopsy and additional&#xD;
             material for the study.&#xD;
&#xD;
          -  INR &lt;1.5; Platelets &gt; 50000 / μL&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient under age of 18 years.&#xD;
&#xD;
          -  Patient under Plavix or Effient or Ticlid without possibility of suspension for 5&#xD;
             days, low molecular weight heparin without possibility of suspension of the dose&#xD;
             before the intervention, or Fondaparinux without possibility of suspension, or ReoPro&#xD;
             without possibility of suspension for 24h and aPTT &lt;50s and ACT &lt;150s, or Integrilin&#xD;
             or Aggrastat or Argatroban without possibility of suspension 4 H before the&#xD;
             intervention, or Angiomax without possibility of suspending 2H to 3H if CrCL&gt; 50 mL /&#xD;
             min or 3H to 5h if CrCL &lt;50 mL / min before the intervention or and Pradaxa without&#xD;
             possibility of suspension 2 to 3 days if CrCL&gt; 50 mL / min or 3 to 5 days if CrCL &lt;50&#xD;
             mL / min before the procedure&#xD;
&#xD;
          -  Patient under desmopressin acetate (DDAVP)&#xD;
&#xD;
          -  Patient with HIV or Hepatitis C positive or Hepatitis B infection, defined by either a&#xD;
             detection of the HBs antigen or the presence of anti HBc antibodies without HBs&#xD;
             antibody detectable.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 10, 2019</study_first_submitted>
  <study_first_submitted_qc>May 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 16, 2019</study_first_posted>
  <last_update_submitted>October 25, 2021</last_update_submitted>
  <last_update_submitted_qc>October 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

